SCHEMBL5402275

SCHEMBL5402275

COc1ccc(CN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
EPHX2 P34913 5/20 0.53
NR1H4 Q96RI1 5/20 0.53
RAB9A P51151 4/20 0.53
NPC1 O15118 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HPGD P15428 3/20 0.46
LPAR1 Q92633 1/20 0.45
CXCR3 P49682 1/20 0.45
LMNA P02545 1/20 0.44
PDK1 Q15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403175 0.93 HDAC1 (0.59) HDAC1HDAC6RAB9ANPC1MEN1
SCHEMBL5397479 0.93 HDAC1 (0.61) HDAC1HDAC6RAB9ANPC1MEN1
SCHEMBL5407093 0.93 HDAC1 (0.61) HDAC1HDAC6RAB9ANPC1MEN1
SCHEMBL5409367 0.93 LMNA (0.52) HDAC1HDAC6EPHX2NR1H4RAB9A
SCHEMBL5405685 0.92 EPHX2 (0.53) HDAC1HDAC6EPHX2NR1H4RAB9A
SCHEMBL5392370 0.90 HDAC1 (0.55) HDAC1HDAC6RAB9ANPC1ALDH1A1
SCHEMBL5395516 0.89 HDAC1 (0.55) HDAC1HDAC6RAB9ANPC1MEN1
SCHEMBL5403231 0.89 HDAC1 (0.55) HDAC1HDAC6RAB9ANPC1KMT2A
SCHEMBL5402486 0.89 HDAC1 (0.55) HDAC1HDAC6RAB9ANPC1KMT2A
SCHEMBL5399096 0.89 CYP1A2 (0.47) HDAC1HDAC6EPHX2NR1H4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB HDAC1 2189/4885HDAC6 2386/4885EPHX2 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.